

2019 Future of Friedreich Ataxia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

<https://marketpublishers.com/r/211B80D253EEN.html>

Date: February 2019

Pages: 70

Price: US\$ 2,199.00 (Single User License)

ID: 211B80D253EEN

Abstracts

The global demand for Friedreich Ataxia treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Friedreich Ataxia pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Friedreich Ataxia pipeline companies from advancing their products into Phase 3 or Phase 4.

Friedreich Ataxia Report Description-

The 2019 pipeline study on Friedreich Ataxia pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Friedreich Ataxia pipeline compounds.

The Friedreich Ataxia pipeline guide presents information on all active drugs currently being developed for Friedreich Ataxia. The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Friedreich Ataxia pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Friedreich Ataxia drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Friedreich Ataxia product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Friedreich Ataxia pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Friedreich Ataxia pipeline report includes-

An overview of Friedreich Ataxia disease including symptoms, causes, diagnosis and available treatment options is provided.

Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc

Phase wise count of Friedreich Ataxia pipeline

Company wise list of Friedreich Ataxia pipeline

Mechanism of Action wise Friedreich Ataxia pipeline

For each pipeline candidate, the following details are provided

Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)

Current status of development

Drug overview

Mechanism of Action

Pre-clinical and Clinical Trials/Results

Company Overview and Recent Developments

REASONS TO BUY

The report is designed to help industry executives promote the success and continued growth of their organizations

Get clear understanding of the entire Friedreich Ataxia pipeline, with details on active projects

Stay ahead of the competition through comprehensive knowledge of Friedreich Ataxia pipeline progress

Get in detail information of each product with updated information on each project along with key milestones

Gain clear insights into companies participating in Friedreich Ataxia pipeline along with progress of each of the company's products and information on associations/collaborations/licensing data

Get trial information for each pipeline product under development

Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

- 1.1 List of Tables
- 1.2 List of Figures

2. GLOBAL FRIEDREICH ATAXIA PIPELINE OVERVIEW

- 2.1 Key Findings, 2019
- 2.2 Disease Overview
- 2.3 Research Methodology

3. EXECUTIVE SUMMARY

- 3.1 Friedreich Ataxia Drugs under active development, H1- 2019
- 3.2 Pipeline Drugs in Early Stage of Development
 - 3.2.1 Pre-clinical
 - 3.2.2 Discovery
 - 3.2.3 Phase
 - 3.2.4Phase
- 3.3 Pipeline Drugs in Advanced Stage of Development
 - 3.3.1 Phase
 - 3.3.2 Pre-registration
- 3.4 Companies involved in Friedreich Ataxia pipeline, H1- 2019
- 3.5 Mechanism of Action wise Friedreich Ataxia Pipeline Candidates

4 ADVERUM BIOTECHNOLOGIES INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 4.1 Adverum Biotechnologies Inc Business Profile
- 4.2 Adverum Biotechnologies Inc Friedreich Ataxia Drug Details
- 4.3 Drug Snapshot
 - 4.3.1 Originator
 - 4.3.2 Collaborator/Co-Developer
 - 4.3.3 Route of Administration
 - 4.3.4 Orphan Drug/Fast Track/Special Designation
 - 4.3.5 Geography
 - 4.3.6 Type of Molecular Entity
 - 4.3.7 Current Status

- 4.4 Drug Overview
- 4.5 Drug Mechanism of Action
- 4.6 Clinical/Pre-clinical Trial Details
- 4.7 Latest Drug Developments

5 AGIOS PHARMACEUTICALS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 5.1 Agios Pharmaceuticals Inc Business Profile
- 5.2 Agios Pharmaceuticals Inc Friedreich Ataxia Drug Details
- 5.3 Drug Snapshot
 - 5.3.1 Originator
 - 5.3.2 Collaborator/Co-Developer
 - 5.3.3 Route of Administration
 - 5.3.4 Orphan Drug/Fast Track/Special Designation
 - 5.3.5 Geography
 - 5.3.6 Type of Molecular Entity
 - 5.3.7 Current Status
- 5.4 Drug Overview
- 5.5 Drug Mechanism of Action
- 5.6 Clinical/Pre-clinical Trial Details
- 5.7 Latest Drug Developments

6 AMYLYX PHARMACEUTICAL CORP FRIEDREICH ATAXIA PIPELINE DETAILS

- 6.1 Amylyx Pharmaceutical Corp Business Profile
- 6.2 Amylyx Pharmaceutical Corp Friedreich Ataxia Drug Details
- 6.3 Drug Snapshot
 - 6.3.1 Originator
 - 6.3.2 Collaborator/Co-Developer
 - 6.3.3 Route of Administration
 - 6.3.4 Orphan Drug/Fast Track/Special Designation
 - 6.3.5 Geography
 - 6.3.6 Type of Molecular Entity
 - 6.3.7 Current Status
- 6.4 Drug Overview
- 6.5 Drug Mechanism of Action
- 6.6 Clinical/Pre-clinical Trial Details
- 6.7 Latest Drug Developments

7 BIOELECTRON TECHNOLOGY CORP FRIEDREICH ATAXIA PIPELINE DETAILS

- 7.1 BioElectron Technology Corp Business Profile
- 7.2 BioElectron Technology Corp Friedreich Ataxia Drug Details
- 7.3 Drug Snapshot
 - 7.3.1 Originator
 - 7.3.2 Collaborator/Co-Developer
 - 7.3.3 Route of Administration
 - 7.3.4 Orphan Drug/Fast Track/Special Designation
 - 7.3.5 Geography
 - 7.3.6 Type of Molecular Entity
 - 7.3.7 Current Status
- 7.4 Drug Overview
- 7.5 Drug Mechanism of Action
- 7.6 Clinical/Pre-clinical Trial Details
- 7.7 Latest Drug Developments

8 BIOMARIN PHARMACEUTICAL INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 8.1 BioMarin Pharmaceutical Inc Business Profile
- 8.2 BioMarin Pharmaceutical Inc Friedreich Ataxia Drug Details
- 8.3 Drug Snapshot
 - 8.3.1 Originator
 - 8.3.2 Collaborator/Co-Developer
 - 8.3.3 Route of Administration
 - 8.3.4 Orphan Drug/Fast Track/Special Designation
 - 8.3.5 Geography
 - 8.3.6 Type of Molecular Entity
 - 8.3.7 Current Status
- 8.4 Drug Overview
- 8.5 Drug Mechanism of Action
- 8.6 Clinical/Pre-clinical Trial Details
- 8.7 Latest Drug Developments

9 BIOVISTA INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 9.1 Biovista Inc Business Profile
- 9.2 Biovista Inc Friedreich Ataxia Drug Details
- 9.3 Drug Snapshot

- 9.3.1 Originator
- 9.3.2 Collaborator/Co-Developer
- 9.3.3 Route of Administration
- 9.3.4 Orphan Drug/Fast Track/Special Designation
- 9.3.5 Geography
- 9.3.6 Type of Molecular Entity
- 9.3.7 Current Status
- 9.4 Drug Overview
- 9.5 Drug Mechanism of Action
- 9.6 Clinical/Pre-clinical Trial Details
- 9.7 Latest Drug Developments

10 CARDERO THERAPEUTICS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 10.1 Cardero Therapeutics Inc Business Profile
- 10.2 Cardero Therapeutics Inc Friedreich Ataxia Drug Details
- 10.3 Drug Snapshot
 - 10.3.1 Originator
 - 10.3.2 Collaborator/Co-Developer
 - 10.3.3 Route of Administration
 - 10.3.4 Orphan Drug/Fast Track/Special Designation
 - 10.3.5 Geography
 - 10.3.6 Type of Molecular Entity
 - 10.3.7 Current Status
- 10.4 Drug Overview
- 10.5 Drug Mechanism of Action
- 10.6 Clinical/Pre-clinical Trial Details
- 10.7 Latest Drug Developments

11 CHONDRIAL THERAPEUTICS LLC FRIEDREICH ATAXIA PIPELINE DETAILS

- 11.1 Chondrial Therapeutics LLC Business Profile
- 11.2 Chondrial Therapeutics LLC Friedreich Ataxia Drug Details
- 11.3 Drug Snapshot
 - 11.3.1 Originator
 - 11.3.2 Collaborator/Co-Developer
 - 11.3.3 Route of Administration
 - 11.3.4 Orphan Drug/Fast Track/Special Designation
 - 11.3.5 Geography

- 11.3.6 Type of Molecular Entity
- 11.3.7 Current Status
- 11.4 Drug Overview
- 11.5 Drug Mechanism of Action
- 11.6 Clinical/Pre-clinical Trial Details
- 11.7 Latest Drug Developments

12 HORIZON PHARMA PLC FRIEDREICH ATAXIA PIPELINE DETAILS

- 12.1 Horizon Pharma Plc Business Profile
- 12.2 Horizon Pharma Plc Friedreich Ataxia Drug Details
- 12.3 Drug Snapshot
 - 12.3.1 Originator
 - 12.3.2 Collaborator/Co-Developer
 - 12.3.3 Route of Administration
 - 12.3.4 Orphan Drug/Fast Track/Special Designation
 - 12.3.5 Geography
 - 12.3.6 Type of Molecular Entity
 - 12.3.7 Current Status
- 12.4 Drug Overview
- 12.5 Drug Mechanism of Action
- 12.6 Clinical/Pre-clinical Trial Details
- 12.7 Latest Drug Developments

13 IXCHEL PHARMA LLC FRIEDREICH ATAXIA PIPELINE DETAILS

- 13.1 Ixchel Pharma LLC Business Profile
- 13.2 Ixchel Pharma LLC Friedreich Ataxia Drug Details
- 13.3 Drug Snapshot
 - 13.3.1 Originator
 - 13.3.2 Collaborator/Co-Developer
 - 13.3.3 Route of Administration
 - 13.3.4 Orphan Drug/Fast Track/Special Designation
 - 13.3.5 Geography
 - 13.3.6 Type of Molecular Entity
 - 13.3.7 Current Status
- 13.4 Drug Overview
- 13.5 Drug Mechanism of Action
- 13.6 Clinical/Pre-clinical Trial Details

13.7 Latest Drug Developments

14 JUPITER ORPHAN THERAPEUTICS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 14.1 Jupiter Orphan Therapeutics Inc Business Profile
- 14.2 Jupiter Orphan Therapeutics Inc Friedreich Ataxia Drug Details
- 14.3 Drug Snapshot
 - 14.3.1 Originator
 - 14.3.2 Collaborator/Co-Developer
 - 14.3.3 Route of Administration
 - 14.3.4 Orphan Drug/Fast Track/Special Designation
 - 14.3.5 Geography
 - 14.3.6 Type of Molecular Entity
 - 14.3.7 Current Status
- 14.4 Drug Overview
- 14.5 Drug Mechanism of Action
- 14.6 Clinical/Pre-clinical Trial Details
- 14.7 Latest Drug Developments

15 PANORAMA RESEARCH INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 15.1 Panorama Research Inc Business Profile
- 15.2 Panorama Research Inc Friedreich Ataxia Drug Details
- 15.3 Drug Snapshot
 - 15.3.1 Originator
 - 15.3.2 Collaborator/Co-Developer
 - 15.3.3 Route of Administration
 - 15.3.4 Orphan Drug/Fast Track/Special Designation
 - 15.3.5 Geography
 - 15.3.6 Type of Molecular Entity
 - 15.3.7 Current Status
- 15.4 Drug Overview
- 15.5 Drug Mechanism of Action
- 15.6 Clinical/Pre-clinical Trial Details
- 15.7 Latest Drug Developments

16 PTC THERAPEUTICS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 16.1 PTC Therapeutics Inc Business Profile
- 16.2 PTC Therapeutics Inc Friedreich Ataxia Drug Details
- 16.3 Drug Snapshot
 - 16.3.1 Originator
 - 16.3.2 Collaborator/Co-Developer
 - 16.3.3 Route of Administration
 - 16.3.4 Orphan Drug/Fast Track/Special Designation
 - 16.3.5 Geography
 - 16.3.6 Type of Molecular Entity
 - 16.3.7 Current Status
- 16.4 Drug Overview
- 16.5 Drug Mechanism of Action
- 16.6 Clinical/Pre-clinical Trial Details
- 16.7 Latest Drug Developments

17 REATA PHARMACEUTICALS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 17.1 Reata Pharmaceuticals Inc Business Profile
- 17.2 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Details
- 17.3 Drug Snapshot
 - 17.3.1 Originator
 - 17.3.2 Collaborator/Co-Developer
 - 17.3.3 Route of Administration
 - 17.3.4 Orphan Drug/Fast Track/Special Designation
 - 17.3.5 Geography
 - 17.3.6 Type of Molecular Entity
 - 17.3.7 Current Status
- 17.4 Drug Overview
- 17.5 Drug Mechanism of Action
- 17.6 Clinical/Pre-clinical Trial Details
- 17.7 Latest Drug Developments

18 RETROTOPE INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 18.1 Retrotape Inc Business Profile
- 18.2 Retrotape Inc Friedreich Ataxia Drug Details
- 18.3 Drug Snapshot
 - 18.3.1 Originator
 - 18.3.2 Collaborator/Co-Developer

- 18.3.3 Route of Administration
- 18.3.4 Orphan Drug/Fast Track/Special Designation
- 18.3.5 Geography
- 18.3.6 Type of Molecular Entity
- 18.3.7 Current Status
- 18.4 Drug Overview
- 18.5 Drug Mechanism of Action
- 18.6 Clinical/Pre-clinical Trial Details
- 18.7 Latest Drug Developments

19 STATEGICS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 19.1 STATegics Inc Business Profile
- 19.2 STATegics Inc Friedreich Ataxia Drug Details
- 19.3 Drug Snapshot
 - 19.3.1 Originator
 - 19.3.2 Collaborator/Co-Developer
 - 19.3.3 Route of Administration
 - 19.3.4 Orphan Drug/Fast Track/Special Designation
 - 19.3.5 Geography
 - 19.3.6 Type of Molecular Entity
 - 19.3.7 Current Status
- 19.4 Drug Overview
- 19.5 Drug Mechanism of Action
- 19.6 Clinical/Pre-clinical Trial Details
- 19.7 Latest Drug Developments

20 TAKEDA PHARMACEUTICAL CO LTD FRIEDREICH ATAXIA PIPELINE DETAILS

- 20.1 Takeda Pharmaceutical Co Ltd Business Profile
- 20.2 Takeda Pharmaceutical Co Ltd Friedreich Ataxia Drug Details
- 20.3 Drug Snapshot
 - 20.3.1 Originator
 - 20.3.2 Collaborator/Co-Developer
 - 20.3.3 Route of Administration
 - 20.3.4 Orphan Drug/Fast Track/Special Designation
 - 20.3.5 Geography
 - 20.3.6 Type of Molecular Entity

- 20.3.7 Current Status
- 20.4 Drug Overview
- 20.5 Drug Mechanism of Action
- 20.6 Clinical/Pre-clinical Trial Details
- 20.7 Latest Drug Developments

21 VOYAGER THERAPEUTICS INC FRIEDREICH ATAXIA PIPELINE DETAILS

- 21.1 Voyager Therapeutics Inc Business Profile
- 21.2 Voyager Therapeutics Inc Friedreich Ataxia Drug Details
- 21.3 Drug Snapshot
 - 21.3.1 Originator
 - 21.3.2 Collaborator/Co-Developer
 - 21.3.3 Route of Administration
 - 21.3.4 Orphan Drug/Fast Track/Special Designation
 - 21.3.5 Geography
 - 21.3.6 Type of Molecular Entity
 - 21.3.7 Current Status
- 21.4 Drug Overview
- 21.5 Drug Mechanism of Action
- 21.6 Clinical/Pre-clinical Trial Details
- 21.7 Latest Drug Developments

22. LATEST FRIEDREICH ATAXIA DRUG PIPELINE DEVELOPMENTS, 2019

23. APPENDIX

- 23.1 About Us
- 23.2 Sources and Methodology
- 23.3 Contact Information

I would like to order

Product name: 2019 Future of Friedreich Ataxia R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

Product link: <https://marketpublishers.com/r/211B80D253EEN.html>

Price: US\$ 2,199.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/211B80D253EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

